Short Interest in Vivani Medical, Inc. (NASDAQ:VANI) Decreases By 25.4%

Vivani Medical, Inc. (NASDAQ:VANI) was the recipient of a significant decrease in short interest in February. As of February 27th, there was short interest totaling 290,597 shares, a decrease of 25.4% from the February 12th total of 389,363 shares. Approximately 0.7% of the company’s stock are sold short. Based on an average daily volume of 201,565 shares, the short-interest ratio is currently 1.4 days. Based on an average daily volume of 201,565 shares, the short-interest ratio is currently 1.4 days. Approximately 0.7% of the company’s stock are sold short.

Vivani Medical Trading Down 0.9%

NASDAQ:VANI opened at $1.10 on Monday. Vivani Medical has a 1 year low of $0.91 and a 1 year high of $1.92. The firm’s fifty day simple moving average is $1.28 and its 200 day simple moving average is $1.36. The firm has a market capitalization of $85.99 million, a PE ratio of -2.44 and a beta of 3.17.

Insider Buying and Selling

In other Vivani Medical news, Director Gregg Williams bought 1,737,765 shares of the stock in a transaction on Thursday, January 15th. The shares were purchased at an average cost of $1.14 per share, with a total value of $1,981,052.10. Following the completion of the transaction, the director directly owned 26,564,109 shares of the company’s stock, valued at $30,283,084.26. This represents a 7.00% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 46.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Vivani Medical

Hedge funds have recently bought and sold shares of the company. State Street Corp increased its stake in shares of Vivani Medical by 12.5% in the fourth quarter. State Street Corp now owns 144,865 shares of the company’s stock worth $178,000 after purchasing an additional 16,070 shares during the period. Susquehanna International Group LLP boosted its stake in Vivani Medical by 100.5% during the 3rd quarter. Susquehanna International Group LLP now owns 32,314 shares of the company’s stock valued at $46,000 after purchasing an additional 16,200 shares during the period. Citadel Advisors LLC bought a new stake in Vivani Medical during the 3rd quarter valued at approximately $26,000. Panagora Asset Management Inc. acquired a new stake in Vivani Medical in the 2nd quarter valued at approximately $25,000. Finally, Jane Street Group LLC acquired a new stake in Vivani Medical in the 4th quarter valued at approximately $60,000. 6.78% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vivani Medical in a research note on Friday, January 9th. Wall Street Zen raised Vivani Medical to a “sell” rating in a research note on Saturday, November 22nd. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $4.00.

About Vivani Medical

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.